In the second clinical case, Brentjens and colleagues described a patient with bulky CLL and extensive previous chemotherapy treatment who received autologous T cells expressing a second generation anti-CD19. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.